The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://aruniqft340106.wikilinksnews.com/6607854/retatrutide_vs_tirzepatide_a_comparative_analysis